Maiken Keson-Brookes - Jul 22, 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Signature
/s/ Maiken Keson-Brookes
Stock symbol
MURA
Transactions as of
Jul 22, 2025
Transactions value $
-$6,379
Form type
4
Date filed
7/23/2025, 05:00 PM
Previous filing
Jul 22, 2025
Next filing
Dec 5, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Keson-Brookes Maiken Chief Legal Officer and Secretary C/O MURAL ONCOLOGY PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND /s/ Maiken Keson-Brookes 2025-07-23 0001693805

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MURA Ordinary Shares Sale -$6.38K -2.57K -3.6% $2.48 68.8K Jul 22, 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.46 to $2.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 62,203 unvested restricted stock units.

Remarks:

Chief Legal Officer and Secretary